Company Overview and News
San Miguel (OTCPK:SMGBY) produced full year results which were very well received by the market. Growth across all its sectors looks set to continue in 2018. It remains a good play on the growing Philippines economy as a whole. In addition there is the possibility of new developments which would cause its stock price to rise faster than the current organic growth and good valuation would imply.
What is set to become the largest share sale in Philippine history may become even bigger after San Miguel Corp.’s chief said he could offer as much as a third of the conglomerate’s soon-to-be-consolidated food and beverage businesses to the investing public.
SAN MIGUEL Pure Foods Company, Inc. (SMPFC) said it has secured the Securities and Exchange Commission (SEC)’s approval to amend its name and primary purpose, among others, to reflect the consolidation of the San Miguel group’s traditional businesses.
San Miguel Pure Foods Company, Inc. (SMPF) said it has secured the Securities and Exchange Commission (SEC)’s approval to amend its name and primary purpose, among others, to reflect the consolidation of the San Miguel group’s traditional businesses.
LOCAL DEBT watcher Philippine Rating Services Corp. (PhilRatings) maintained the top credit rating for San Miguel Brewery, Inc. (SMBI)’s P34.81-billion bonds, citing its continued positive performance and strong position in the market.
AS IN fashion, food also follows trends that mirror what society at present wants (but says they need). San Miguel Pure Foods played trend forecaster this year when the company showcased food trends that it predicts will sizzle this year.
ENCOURAGED by the positive economic outlook, corporates are expected to raise a record amount of capital from the stock market this year, even with a slowdown in initial public offerings (IPO), First Metro Investment Corp. (FMIC) said in a briefing on Thursday.
Filipino chefs have been making big waves in the culinary arena. In the local scene, there are a good number—both well-known and budding ones—who have made significant contributions and impact this year that made our dining experience extra-exciting.
11h - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
11h - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...
as of ET